Nicotinic acid in the treatment of schizophrenias. Practical and theoretical considerations.
After reviewing the literature on nicotinic acid in the treatment of schizophrenia, the authors present the results of the Canadian collaborative study. The data indicate that nicotinic acid has no therapeutic effect of schizophrenia.
D000323:Adrenochrome / Q000378:metabolism; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D009243:NAD / Q000172:deficiency; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D010383:Pellagra / Q000150:complications; D010640:Phenothiazines; D011736:Pyridoxine / Q000008:administration & dosage / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine
D014150:Antipsychotic Agents; D009539:Nicotinic Acids; D010640:Phenothiazines; D009243:NAD; D000323:Adrenochrome; D011736:Pyridoxine; D001205:Ascorbic Acid